Antitumor effect of gracillin on the growth of NSCLC cell-line-derived and patient-derived xenograft tumors and mutant-Kras-driven spontaneous lung tumors with minimal toxicity in vivo. Here, KRAS is linked to non-small cell lung carcinoma.